 Home > Active Pharmaceutical Ingredients > Other Chemical Drugs > 2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one dihydrochloride for Sale > Trilaciclib hydrochloride

Trilaciclib hydrochloride

Name: Trilaciclib hydrochloride
Brand: Simcere
SKU: pr2412171409
Price: 1000 USD
Availability: InStock

GMP COA

Unit Price: Get Latest Price 

CAS No.:

1977495-97-8

Grade:

Pharmaceutical Grade

Content:

99%

Port:

上海

Brand:

Simcere

Packaging:

5kg/Cardboard Drum

Price valid (until):

2025-01-17

Contact Supplier

 Chat Now

Simcere Pharmaceutical Co.,Ltd

Company Type:

Manufactory

Location:

China

Qualification:

Main Products:

Diosmectite,Bedaquiline FuMarate,Iguratimod,Edoxaban Tosylate,Edaravone,Borneol

 Visit Store

Product Description
Seller Information

Description

Product Detail

Corsaila® (trilacizil hydrochloride for injection) is the world's first innovative drug developed by Innovent and G1 Therapeutics that is administered before chemotherapy and has a full-lineage bone marrow protection effect.

In August 2020, Innovent and G1 Therapeutics reached an exclusive licensing agreement to obtain the development and commercialization rights of trilacizil for all indications in Greater China. [5]
In July 2022, trilacizil hydrochloride for injection was approved for import registration and marketing by the National Medical Products Administration.

On February 12, 2023, Innovent's subsidiary, Innovent Zaiming, which focuses on the development and commercialization of innovative anti-tumor drugs, announced that Corsaila (trilacizil hydrochloride for injection), a global innovative drug for chemotherapy bone marrow protection, has started full commercial circulation in China.

On November 28, 2024, trilacizil hydrochloride for injection was included in the new version of the National Medical Insurance Drug Catalogue.

Items	Specifications
Storage conditions:	Store at -20°C
Form:	Solid
Color:	Light yellow to yellow
Water solubility:	Water: ≥ 100 mg/mL (192.50 mM)

Certificates

Basic Info

Product Name:

2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one dihydrochloride

Other Name:

Trilaciclib hydrochloride;1977495-97-8;Trilaciclib dihydrochloride;Trilaciclib (hydrochloride);UNII-4BX07W725T;4BX07W725T;trilaciclib 2HCl;G1T28 dihydrochloride;CHEMBL4650272;Trilaciclib hydrochloride(G1T28)

CAS No.:

1977495-97-8

Molecular Formula:

C24H32Cl2N8O

InChIKeys:

BRCYOXKEDFAUSA-UHFFFAOYSA-N

Molecular Weight:

519.5

Exact Mass:

518.2076131

UNII:

4BX07W725T

Categories:

Other Chemical Drugs

Characteristics

Seller Information

Business Type:
Manufactory

Main Products:
Diosmectite,Bedaquiline FuMarate,Iguratimod,Edoxaban Tosylate,Edaravone,Borneol

Location:
No. 109, Changfenghe Road, Jiangbei New District, Nanjing

Payment Terms:
100% TT in advance

Average lead Time:
30

Total Annual Revenue:
Above $100 million

Total Employees:
Above 1000

Year of Establishment:
2022

Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D. We are committed to "providing today's patients with medicines of the future" across the following core therapeutic areas: oncology, central nervous system, autoimmunity and anti-infection. Furthermore, we are also actively expanding our presence in disease areas with significant clinical needs in the future.

Our industry-leading capabilities and commitment to synergistic innovation have also enabled various strategic collaborations and we are seen as the partner of choice by innovative biopharmaceutical companies, medical institutes, and research teams in China and globally.
Country Product Purchase Quantity Date Posted

Post an enquiry for this product

Trilaciclib hydrochloride

Product Description

Seller Information

Related Searches